Testosterone Patches Improve Low Sexual Desire Disorder
Evidence suggests that transdermal testosterone patches may relieve symptoms of hypoactive sexual desire disorder (HSDD) in postmenopausal women.
Diagnosis & Disease Information
Phase 3 Study Update of LibiGel for Female Sexual Dysfunction
BioSante announced positive safety data from ongoing Phase 3 trials of LibiGel (testosterone) for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women.
Postmenopausal HRT Improves Sexual Function
Twelve months of daily oral hormonal replacement therapy with estradiol plus dihydrogesterone (HRT), dehydroepiandrosterone (DHEA), or tibolone improves sexual function and frequency in early postmenopausal women.
Phase 3 Study of Bazedoxifene/Conjugated Estrogen for Menopausal Symptoms
Pfizer announced results from its Phase 3 safety study of bazedoxifene/conjugated estrogen (BZA/CE) for the treatment of moderate-to-severe hot flashes, vulvar and vaginal atrophy and the prevention of osteoporosis in women following menopause.
Phase 3 Trial of Oral Calcitonin for Postmenopausal Osteoporosis
Tarsa Therapeutics announced positive results from its Phase 3 ORACAL study of oral recombinant salmon calcitonin for the treatment of postmenopausal osteoporosis.
Phase 3 study of LibiGel for female sexual dysfunction
BioSante announced positive safety data from ongoing Phase 3 trials of LibiGel (testosterone) for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women.
Phase 3, Phase 2 trials of oral recombinant calcitonin for postmenopausal osteoporosis
Tarsa Therapeutics announced completion of its global Phase 3 ORACAL trial evaluating a once-daily, oral recombinant calcitonin for the treatment of postmenopausal osteoporosis in 565 patients.
Caltrate Soft Chews for calcium and Vitamin D supplementation
Wyeth Consumer Healthcare has expanded the Caltrate product line with the launch of Caltrate Soft Chews.
FDA warns of unintentional exposure to estrogen with Evamist
The FDA has notified healthcare professionals and patients that it is reviewing reports of adverse effects from Evamist (estradiol transdermal spray, from Ther-Rx) in children who may have been unintentionally exposed to the drug through skin contact with women using this product.
